ERBB2 and breast carcinoma: A greater percentage of patients with HR-positive status was noted in the HER2-low group compared to those in the remaining two groups (73.6% vs 51.7%, 51.6%, P < 0.01), indicating a relatively higher prevalence of luminal breast cancer subtype in the HER2-low MBC.